Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

Neuro-Oncology

Volumn 13, Issue 3, 2011, Pages 324-333

  Sampson, John H ^a,b,e   Aldape, Kenneth D ^d,e   Archer, Gary E ^a,e   Coan, April ^c,e   Desjardins, Annick ^a,e   Friedman, Allan H ^a,e   Friedman, Henry S ^a,b,e   Gilbert, Mark R ^b,e   Herndon, James E ^b,e   McLendon, Roger E ^b,e   Mitchell, Duane A ^a,e   Reardon, David A ^a,e   Sawaya, Raymond ^b,e   Schmittling, Robert ^a,e   Shi, Weiming ^b,e   Vredenburgh, James J ^a,e   Bigner, Darell D ^a,b,e   Heimberger, Amy B ^b,e  

^a Division of Neurosurgery   (United States)

^b Department of Pathology ^*  (United States)

^c Cancer Center Biostatistics   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor mutant III; Glioblastoma multiforme; Immune therapy; Temozolomide

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; LEUCYLGLUTAMYLGLUTAMYLLYSYLLYSYLGLYCYLASPARAGINYLTYROSYLVALYLVALYLTHREONYLASPARTYLHISTIDYLCYSTEINE; PEPTIDE VACCINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAPHORESIS; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; FLUSHING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPERSALIVATION; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALAISE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; THORAX PAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DACARBAZINE; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOENZYME TECHNIQUES; LYMPHOPENIA; MALE; MIDDLE AGED; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 79955784386     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq157     Document Type: Article

References (26)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA. 1990;87:4207-4211.
3. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11:1462-1466. (Pubitemid 40315227)
4. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA. 1992;89:2965-2969.
5. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006;12:5064-5073. (Pubitemid 44453332)
6. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995;55:3140-3148.
7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995;6:1251-1259.
8. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J. 1997;324:855-861. (Pubitemid 27285544)
9. Boockvar JA, Kapitonov D, Kapoor G, et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci. 2003;24:1116-1130. (Pubitemid 38091521)
10. Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol. 2004;72: 267-273. (Pubitemid 39265379)
11. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem. 2000;275:17358-17363. (Pubitemid 30430771)
12. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9:4247-4254. (Pubitemid 37204046)
13. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J Clin Oncol. 2004;22:610-616. (Pubitemid 41095063)
14. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol. 2005;23:4235-4236; author reply 4236. (Pubitemid 46211332)
15. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-4367. (Pubitemid 28450038)
16. Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA. 2002;99:931-936. (Pubitemid 34106613)
17. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854. (Pubitemid 35231542)
18. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110:185-192. (Pubitemid 34787355)
19. Khoruts A, Fraser JM. A causal link between lymphopenia and autoimmunity. Immunol Lett. 2005;98:23-31. (Pubitemid 40409815)
20. Tanchot C, Rosado MM, Agenes F, Freitas AA, Rocha B. Lymphocyte homeostasis. Semin Immunol. 1997;9:331-337. (Pubitemid 28021490)
21. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
22. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
23. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29-38.
24. Curran WJ, Jr., Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710. (Pubitemid 23133591)
25. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563-2569. (Pubitemid 46630635)
26. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine- DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011. (Pubitemid 36560766)